Recursion Acquires Cyclica and Valence to Bolster Digital Chemistry and Generative AI

Recursion (NASDAQ: RXRX) entered into agreements to acquire two AI-enabled drug discovery companies, Cyclica (Toronto) and Valence (Montréal), for aggregate reported purchase prices of $40.0 million and $47.5 million respectively, payable primarily in Recursion equity and exchangeable subsidiary shares. The acquisitions add digital-chemistry, proteome-wide prediction and low-data generative chemistry capabilities to Recursion's RecursionOS and research organization to accelerate its AI-first drug discovery platform.